Dickey Jacqueline S, Dickey Burton F, Alousi Amin M, Champlin Richard E, Sheshadri Ajay
University of Utah, Department of Internal Medicine, Salt Lake City, UT, USA.
The University of Texas MD Anderson Cancer Center, Department of Pulmonary Medicine, Houston, TX, USA.
Respir Med Case Rep. 2024 Mar 11;49:102001. doi: 10.1016/j.rmcr.2024.102001. eCollection 2024.
Bronchiolitis obliterans (BO) is a form of graft-versus-host disease (GVHD) in the lung and manifests as moderate to severe airflow obstruction after hematopoietic stem cell transplantation (HCT). New-onset airflow obstruction on spirometry is considered diagnostic of bronchiolitis obliterans syndrome (BOS). BOS affects about 5% of all HCT recipients. In general, BO is thought of as a late complication of HCT, usually occurring after day 100 post-transplantation. However, the onset of airflow obstruction can be rapid and is most often irreversible even with treatment. We describe a patient who rapidly developed severe airflow obstruction less than one month after transplantation following the development of upper airway symptoms. Despite aggressive immunosuppression, the patient had no improvement in airflow obstruction. We hypothesize that early screening and treatment may help prevent BOS after HCT.
闭塞性细支气管炎(BO)是肺部移植物抗宿主病(GVHD)的一种形式,在造血干细胞移植(HCT)后表现为中度至重度气流阻塞。肺活量测定中出现新发气流阻塞被认为是闭塞性细支气管炎综合征(BOS)的诊断依据。BOS影响约5%的所有HCT受者。一般来说,BO被认为是HCT的晚期并发症,通常发生在移植后100天之后。然而,气流阻塞的发作可能很快,即使经过治疗也大多不可逆。我们描述了一名患者,在出现上呼吸道症状后不到一个月移植后迅速出现严重气流阻塞。尽管进行了积极的免疫抑制治疗,该患者的气流阻塞情况仍无改善。我们推测早期筛查和治疗可能有助于预防HCT后的BOS。